Spectral Medical Inc T.EDT

Paradigm Capital

[Accountprince]

Paradigm Capital is a firm that Chris Seto used to work at.  I presume that's why they get appointed to do all of Spectral's share issuances.  Scott McAuley of Paradigm revalued Spectral today and dropped the share price by $0.30 per share today to $1.90 per share.  The reason?  He now places a value of ZERO on Dialco after the announcement of the iDialco deal.  That confirms my suspicions that there is something in the agreement that will eventually result in the residual value of 30% of Dialco being worthless.  Otherwise why would he give it a ZERO value?  So we've spent many millions of dollars bringing this to the point of full FDA and Health Canada approval for SAMI and DIMI (except home use in the US).  We've hired the best in the business to run Dialco and we have two huge SAMI orders.  And all down the drain because management was incapable of fulfilling the agreement they negotiated with Infomed.  Squandered a huge asset we had through their incompetence.

Time for all the incompetent management to be fired for cause.

[Revten]

Let's Move On People! If you have lost confidence in the Company SELL your Shares and Invest elsewhere! My Portfolio is Up just over 30% from last year at this time. The rest of the Market is down more than that and probably going to get worse! Good Luck! If the SP gets to $.95 cents which is 1/2 Paradigms Target I am Extremely Happy! The Tigress Success is already guaranteed and only a

[hmmmmmmmm]

And puppys and kittens and cotton candy clouds..

[Accountprince]

This post has been removed in accordance with Community Policy

[money4golf]

    Birch Hill Equity Partners own what about 30 million shares of Spectral, why are they ok with this deal?????

[hmmmmmmmm]

There is no way Birch Hill likes this "deal". But Spectral obviously did not fulfill their contract and were left with little to no bargaining chips. On Oct 5th Spectral slipped this into the bottom of their PR: "Dialco has extended its DIMI license agreement with Infomed SA until November 30, 2022 as the parties evaluate strategic options for advancing DIMI through its trial and